Reassessment of medicines containing methylphenidate in attention deficit hyperactivity disorder in response to the instruction from the Directorate-General for Health.
-
Clinical Benefit
Substantial
The actual benefit of QUASYM LP proprietary products is substantial in the context of the overall therapeutic management of ADHD in children aged 6 years old and over when psychological, educational and social management alone prove insufficient.
Listen
